A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
University of Turin, Italy
National Institutes of Health Clinical Center (CC)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
M.D. Anderson Cancer Center
Mayo Clinic
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
University of Leeds
Thomas Jefferson University
Thomas Jefferson University
Northside Hospital, Inc.
Brown University
GWT-TUD GmbH
University of Arkansas
Mayo Clinic
Eastern Cooperative Oncology Group
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
University of Arkansas
City of Hope Medical Center
Fred Hutchinson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Janssen Scientific Affairs, LLC
Thomas Jefferson University
European Myeloma Network B.V.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Universitätsklinikum Hamburg-Eppendorf
Amsterdam UMC, location VUmc
Fred Hutchinson Cancer Center
University of Leeds
University of Leeds
University of Turin, Italy
European Myeloma Network B.V.
University of Leeds
City of Hope Medical Center
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Oncotherapeutics
University of Nebraska
Ohio State University Comprehensive Cancer Center
University of Birmingham
Masonic Cancer Center, University of Minnesota
European Myeloma Network B.V.